Post by The Estée Lauder Companies Inc.

The Estée Lauder Companies is proud to announce a minority investment in 111SKIN, the London-based luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr Yannis Alexandrides MD and Eva Alexandridis, and led by CEO Vanessa Goddevrind. Originally developed to accelerate patients’ healing following procedures, 111SKIN is rooted in decades of clinical expertise and powered by its proprietary NAC Y2™ technology—delivering high-performance, treatment-inspired skin care. “Skin care is entering a new phase—where beauty, longevity and aesthetic procedures are converging, and consumers are seeking products that deliver visible, treatment-inspired results. 111SKIN exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy.” - Stephane de La Faverie, President and CEO, Estée Lauder Companies Since 2012, Dr. Yannis and Eva have built a truly distinctive brand at the intersection of medical expertise and high-performance beauty, with a clear point of view and strong connection to today’s consumer. This investment reflects our Beauty Reimagined vision and our disciplined approach to minority investments—partnering with exceptional founders and brands that are shaping the future of prestige beauty and aligning closely with where our consumers are going. Together, we look forward to supporting 111SKIN’s continued growth—expanding its global reach while preserving the clinical expertise, innovation and distinctive approach that define the brand. Learn more: https://lnkd.in/ej-J3SSU